Flerie (FLERIE.ST) Stock Price

Flerie Price

CLOSED
15.50
​
Market closed

Revenue at Flerie has contracted by 13.8% per year over the past 11 years to 8.80 M SEK. Flerie's net margin stands at -8,601.1%, up from -99,742.0% several years earlier. Analysts set a median price target of 45.90 SEK, implying 196.1% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

Flerie stock price

Access this data via the Eulerpool API

Flerie business model & stock analysis

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

Frequently asked questions about Flerie

Analysts currently set an average price target of 45.90 SEK for the Flerie stock (median: 45.90 SEK), implying +196.1 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Flerie stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Flerie to generate revenue of 8.80 M SEK and earnings per share of -54.00 SEK.

Converted at the current exchange rate, the Flerie share trades at 1.39 EUR (15.50 SEK).

The expected revenue of Flerie is 8.80 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Flerie is -4.18 B SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Flerie is currently -0.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Flerie stock.

The price-to-sales ratio (P/S) of Flerie is currently 136.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Flerie stock.

The Eulerpool Quality Score for Flerie is 4/10.

The ISIN of Flerie is SE0022447348. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Flerie is A2ATYC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Flerie is FLERIE.ST. The ticker symbol is used to trade Flerie shares on the stock exchange.

Fair ValueTerminal
13.79 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
1.47 M SEK
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
Oct 11, 2016
ISIN
SE0022447348
Cusip
W4R29H123
Market capitalization
1.20 B SEKSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.29
P/Se
136.39
EV/EBIT
—
P/B Ratio
0.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-22.41 %
Last updated Oct 9, 2026, 4:03 PM

Flerie Peer Group

All fundamentals and in-depth analysis of Flerie

Our stock analysis for Flerie stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Flerie. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.